0000883975 2025-01-01 2025-12-31 0000883975 2023-12-31 2025-01-01 2025-12-31 0000883975 2024-01-01 2024-12-31 0000883975 2023-01-01 2023-12-31 iso4217:USD false 0000883975 DEF 14A MICROBOT MEDICAL INC. In the fourth quarter of 2023, the Company adopted a clawback policy which implements the incentive-based compensation recovery provisions of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 as required under the listing standards of Nasdaq, and requires recovery of incentive-based compensation received by current or former executive officers during the three fiscal years preceding the date it is determined that the Company is required to prepare an accounting restatement. true The Compensation Committee generally grants stock options to our executive officers, including our named executive officers, on an annual basis, typically during the first quarter of the fiscal year in connection with its annual review of executive compensation. Option grants may also be made on other dates, such as upon the hiring or promotion of an executive officer or in other circumstances the Compensation Committee considers appropriate. Annual option grants to our non-employee directors are generally, but not always, approved by the Board or the Compensation Committee at a Board meeting scheduled immediately after the Company’s annual meeting of stockholders.The Board and the Compensation Committee take material nonpublic information into account when determining the timing and terms of stock option awards, and the Company has not timed the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. false false <table cellpadding="0" cellspacing="0" id="xdx_88C_eecd--PvpTableTextBlock_ze2XMgHdlNvg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Pay vs Performance Disclosure"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_488_eecd--PeoTotalCompAmt_z7VKDf0FuLlg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Summary Compensation Table Total for PEO ($)(1)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td id="xdx_481_eecd--PeoActuallyPaidCompAmt_zSfsEggNmLa8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Compensation Actually Paid to PEO ($)(1)(2)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_483_eecd--NonPeoNeoAvgTotalCompAmt_zmH3qLS8VYs2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Average Summary Compensation Table Total for Non-PEO NEOs ($)(3)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td id="xdx_481_eecd--NonPeoNeoAvgCompActuallyPaidAmt_zjjmUezFoQGl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Average Compensation Actually Paid to Non-PEO NEOs ($)(2)(3)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_486_eecd--TotalShareholderRtnAmt_pp2d_zvcU88jr8Jpd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value of Initial Fixed $100 Investment Based on Total Shareholder Return ($)(4)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_48A_eus-gaap--NetIncomeLoss_pn3n3_zwpwKObNGNQk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Loss ($ in thousands)(5)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_41D_20250101__20251231_zxr6GtoEoVJg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 13%; text-align: center">2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">1,664,945</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 13%; text-align: right">1,858,423</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">522,817</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 12%; text-align: right">581,181</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">66.45</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(13,142</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_415_20240101__20241231_z2R5ZQN6g6p8" style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,241,479</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right">842,682</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">426,357</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right">364,133</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37.21</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,443</td><td style="text-align: left">)</td></tr> <tr id="xdx_418_20230101__20231231_zeIu6Jn3OqTj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,284,123</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right">679,963</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">321,708</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right">271,711</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54.49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,740</td><td style="text-align: left">)</td></tr> </table> 1664945 1858423 522817 581181 66.45

-13142000

1241479 842682 426357 364133 37.21

-11443000

1284123 679963 321708 271711 54.49

-10740000

Harel Gadot served as our principal executive officer (“PEO”) for each of the years presented. Harel Gadot Harel Gadot Harel Gadot Amounts reported as “compensation actually paid” are computed in accordance with Item 402(v) of Regulation S-K and do not reflect the actual amount of compensation earned by or paid to the applicable executives during the applicable year. Compensation actually paid was calculated by deducting from the Summary Compensation Table total the grant date fair value of option awards granted during the year, and adding (i) the year-end fair value of awards granted during the year that remained outstanding and unvested, (ii) for awards granted and vested in the same year, the fair value as of the vesting date, (iii) the change in fair value during the year of awards granted in prior years that remained outstanding and unvested, (iv) for prior-year awards that vested during the year, the change in fair value from the prior year-end to the vesting date, and deducting (v) the prior year-end fair value of any awards forfeited during the year. Fair values were calculated using assumptions consistent with those used to determine grant date fair value under ASC Topic 718. <p id="xdx_891_eecd--CompActuallyPaidVsNetIncomeTextBlock_dU_zBXtZOCudPfj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">Relationship Between Compensation Actually Paid and Performance As a commercial-stage medical device company that is not yet generating recurring, material revenue, we do not use net loss or total shareholder return as performance measures in our executive compensation program. A significant portion of our executives’ compensation consists of stock options, the value of which is directly tied to our stock price. Compensation actually paid did not track our net loss, which was driven primarily by research and development, general and administrative expenses, and regulatory activities. Harel Gadot served as our principal executive officer (“PEO”) for each of the years presented. The non-PEO named executive officers were Rachel Vaknin, Simon Sharon and Juan Diaz-Cartelle for 2025 and 2024, and Rachel Vaknin, Simon Sharon, Juan Diaz-Cartelle and Eyal Morag for 2023. Total shareholder return assumes an initial investment of $100 in our common stock on December 31, 2022 and the reinvestment of any dividends, and is calculated on a cumulative basis through the end of each year presented, giving effect to any stock splits. Represents net loss as reported in our audited consolidated financial statements for the applicable year.